NovaBridge Biosciences (NBP) Non-Current Deferred Tax Liability (2018 - 2022)

NovaBridge Biosciences (NBP) has reported Non-Current Deferred Tax Liability for 3 consecutive years, with $2.5 million the latest figure, recorded in Q4 2022.

• Quarterly Non-Current Deferred Tax Liability fell 10.69% year-over-year to $2.5 million in Q4 2022, while the trailing twelve-month figure through Dec 2022 was $2.5 million (down 10.69% YoY) and the FY2022 annual result came in at $2.6 million, down 7.93% from the prior year.
• Non-Current Deferred Tax Liability retreated to $2.5 million in Q4 2022 per NBP's latest filing, from $2.8 million in the prior quarter.
• Over the last five years, Non-Current Deferred Tax Liability for NBP reached as high as $5.4 million in Q4 2018 and fell as low as $2.5 million in Q4 2022.
• A 3-year average of $3.6 million and a median of $2.8 million in 2021 frame the typical range for Non-Current Deferred Tax Liability.
• The largest YoY upside for Non-Current Deferred Tax Liability was 10.69% in 2022 against a maximum downside of 10.69% in 2022.
• Year by year, Non-Current Deferred Tax Liability stood at $5.4 million in 2018, then slumped by 47.83% to $2.8 million in 2021, then retreated by 10.69% to $2.5 million in 2022.
• According to Business Quant data, Non-Current Deferred Tax Liability over the past three periods registered $2.5 million, $2.8 million, and $5.4 million for Q4 2022, Q4 2021, and Q4 2018 respectively.